Bronchodilator Responsiveness in Children with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis.

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease that occurs in approximately 9% of children with cystic fibrosis (CF) [1]. While ABPA is commonly associated with worsening lung function, differentiating ABPA from other causes of pulmonary function decline, often poses a clinical challenge. This is reflected by major differences among the various diagnostic criteria for ABPA that were suggested in to date 2–5]. A positive bronchodilator response is characteristic for asthma which is a common co-morbidity in CF patients, but whether this is helpful in differentiating ABPA from other causes of deterioration in lung function is currently unclear. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Pollak has nothing to disclose. Conflict of interest: Michelle Shaw has nothing to disclose. Conflict of interest: David Wilson has nothing to disclose. Conflict of interest: Dr. Grasemann has nothing to disclose. Conflict of interest: Dr. Ratjen reports grants and personal fees from Vertex, personal fees from Novartis, personal fees from Bayer, personal fees from Roche, personal fees from Genetech, outside the submitted work.